Related Experiment Video
Updated: Jan 4, 2026
06:48
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
22.0K
Pharmacogenomic Approach to Antimyopia Drug Development: Pathways Lead the Way.
Tatiana V Tkatchenko1, Andrei V Tkatchenko2
1Department of Ophthalmology, Columbia University, New York, NY, USA.
Trends in Pharmacological Sciences
|November 3, 2019
Summary
Myopia, a common vision disorder, results from eye length and optical power mismatch. This review explores genetic pathways and systems genetics for developing new myopia control drugs.
Area of Science:
- Ophthalmology
- Genetics
- Pharmacology
Background:
- Myopia is the most prevalent global eye disorder, characterized by axial elongation.
- Current treatments like atropine have limited efficacy and adverse effects.
- The complex signaling cascade regulating eye axial length hinders antimyopia drug development.
Purpose of the Study:
- To review recent advances in genome-wide studies of myopia development.
- To discuss the potential of systems genetics and pharmacogenomics for novel antimyopia drug discovery.
Main Methods:
- Genome-wide association studies (GWAS) for myopia.
- Analysis of signaling pathways involved in ocular axial length regulation.
- Exploration of systems genetics and pharmacogenomic approaches.
Main Results:
- Identification of complex genetic signaling pathways underlying myopia.
- Highlighting the challenges in developing effective antimyopia therapies.
- Potential for personalized medicine in myopia treatment.
Conclusions:
- Genome-wide studies offer insights into myopia pathogenesis.
- Systems genetics and pharmacogenomics represent promising avenues for future antimyopia drug development.
- Further research is needed to translate genetic findings into clinical applications.
Related Concept Videos
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
194
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
194
01:26Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
01:27Open Angle Glaucoma: Treatment
912
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
912
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.2K
01:21Pharmacodynamics: Overview and Principles
2.7K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.7K
01:24Principles of Drug Action
7.8K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
7.8K